Medical Products News

« February 2005 | Main | April 2005 »

March 31, 2005

RevitaMed Unit of LymphaCare Meets Sales Goals by Offering an Anodyne (Pain Relief) Infrared Therapy Product with Revitamed's Boot Pads

Anodyne is defined in the dictionary as "to alleviate pain". RevitaMed's Infrared Therapy system has been doing just that for hundreds of neuropathy and chronic pain patients, while helping the LymphaCare staff meet its target.

(PRWEB) March 31, 2005 -- LymphaCare Revitamed division has seen a steady increase in sales of both patient and clinical models of the RevitaMed Infrared Therapy system.

Patients and therapists that have seen or used the RevitaMed System for treating chronic pain and circulation problems tend to be surprised and impressed. Most have been unaware that there was any competition or alternative to the more well known brand name of Anodyne® Therapy.

Recently a physical therapy clinic in Oregon that was evaluating an Anodyne® Therapy system in their facility, decided to purchase the RevitaMed System based only on the information provided by LymphaCare and their knowledgeable consultants without even an evaluation. That clinic has since purchased a second RevitaMed Professional Sysem. http://www.revita-med.com

RevitaMed’s Professional system tends to price out about 20%-30% less than the Anodyne® Therapy Pro unit, Physical and Occupational Therapists love the size of the pads, especially the unique boot pads, which cover the entire foot. The Oregon clinic is seeing excellent outcomes for their neuropathy patients. They are also utilizing the large pads to treat large surface areas of the back and leg. They have also been successfully treating the painful condition of Shingles.

Patients have also been discovering why RevitaMed works so well. The Anodyne ® Therapy system is priced at $2995.00 for a new home system. RevitaMed is well over 50% less depending on the pad combination. Many patients that don’t qualify under their insurance, nor have the time to go to physical therapy are thrilled to buy a RevitaMed at a more reasonable price with much larger more powerful infrared pads.

Patients have pointed out that the equine or Equilight (http://www.equilight.com/Products.htm) horse product affiliate of Anodyne ® Therapy, sells the same $29950.00 patient home unit for just $2395.00 on the Equilight.com website That’s a $600.00 difference for what is essentially the same product! This has been making patient's ave some serious questions.

The RevitaMed Infrared Therapy consultants at LymphaCare have comforted customers by addressing the questions and concerns for those evaluating Infrared treatment systems. RevitaMed plans on being around for many years. They are in the process of publishing several clinical studies, and enhancing their current product line to address customer needs and requests.

LymphaCare has been able to meet their sales goals, by educating people on the product differences, excellent pricing, reimbursement issues, and their 30 day money back guarantees for neuropathy patients.

Diabetes, foot pain, neuropathy, and finding a great product as a fair price: all of those play The neuropathy population has many of those things, and any patients with these symptoms who are cost sensitive and demand state of the art technology would be good candidates for the RevitaMed. One LymphaCare employee states, “ it's like getting the Lexus model for the price of a Chevy". The RevitaMed Therapy System does not require a prescription.

RevitaMed products can be found by calling LymphaCare at 800-288-1801.

Posted by Industrial-Manufacturing at 02:58 AM | Comments (0)

NuSil Technology Introduces Fast-Curing Inks for Healthcare

NuSil Technology -- a cutting-edge manufacturer of silicone-based materials for healthcare, aerospace, electronics and photonics -- announces the addition of MED-6613-2, a fast-curing black ink, to its line of silicone inks.

Carpinteria, CA (PRWEB) March 31, 2005 -- NuSil Technology - a cutting-edge manufacturer of silicone-based materials for healthcare, aerospace, electronics and photonics - announces the addition of MED-6613-2, a fast-curing black ink, to its line of silicone inks.

Traditional silicone, or RTV, inks require long curing times and can cause a significant bottleneck in the manufacturing process. In addition, these inks often require long waiting periods prior to handling. MED-6613-2, a black, fast-curing ink can be cured in less than one hour, compared to the 24 hours that RTV inks require for a touchable cure.

“We constantly look for ways to increase the efficiency of our products in customers’ production and assembly lines,” said Brian Nash, vice president of Marketing and Sales. “This ink offers some significant process time advantages over traditional RTV silicone inks”

Each lot of MED-6613-2 is tested for cytotoxicity and trace metals. MED-6613-2 should be evaluated to determine suitability for use in each application.

NuSil Technology’s MED-6613-2 is available in 50-gram kits, two-pint kits and two-gallon kits. More information is available at www.nusil.com/fastcureink. Those interested in different colored inks may contact NuSil Technology directly at www.nusil.com or at 805-684-8780

About NuSil Technology
NuSil is a cutting-edge manufacturer of silicone compounds for healthcare, aerospace, electronics, photonics and other applications that require precise, predictable, cost-effective materials performance. ISO-9001-certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and Europe and provides on-site, in-person application engineering support worldwide.

More information about NuSil Technology can be found at www.nusil.com.

Posted by Industrial-Manufacturing at 02:57 AM | Comments (0)

Advanced Biological Laboratories SA (ABL, S.A) Licenses Stanford HIV Resistance Interpretation Algorithm - Adds to Viroscore Suite Genetic Sequence Database and Analysis Engine

ABL to integrate the Stanford Algorithm with the 5 algorithms currently used in its "global resistance interpretation" report offered in the ViroScore Suite Diagnostic Product.

Topsfield, MA (PRWEB via PR Web Direct) March 30, 2005 -- ABL, SA (A Luxembourg Company) with TherapyEdge Inc. (Durham, NC) today announced it had signed a license agreement to use the Stanford University HIVdb resistance interpretation algorithm in their ViroScorer Report.

The ViroScorer HIV report is part of the ViroScore Suite which provides decision support to HIV doctors by helping them select the best therapy for an HIV patient based on the past and current resistance to HIV drugs. The report has picked up a lot of support from opinion leaders in HIV clinical research as it offers a global interpretation based on research from six leading research centers across the world.

Jean-Claude Schmit, a leading HIV resistance researcher in Europe and the Clinical Director of the Virology Lab at Centre Hospital de Luxembourg, the author of one of the European algorithms in the report, has praised the ABL team for broadening the product line. "The ViroScore Test and the Suite of tools for individual patient treatment and longitudinal research are now unmatched in the Field. Stanford has some of the best researchers in the world and a large pool of genetic sequence data to create and refine their algorithm."

The Stanford Algorithm will round out the resistance interpretation for ABL customers across the globe and in particular in the US where ABL is expanding. Chairman of the board of ABL, Arsene Kronshagen said that, "this algorithm will help us expand in the Americas because it is widely accepted as the standard for HIV resistance interpretation in the region."

ABL sells the resistance interpretation platform to diagnostic companies, HIV researchers and individual physicians treating HIV. The ViroScore Suite of tools includes an enterprise class database for the storage of genetic sequence data, analysis tools for reporting on the relationships between clinical outcomes and virus mutations, phylogenetic analysis of sequence groups and numerous tools to assist the physicians and researchers in optimizing the use of complex genetic data.

ABL will also use the Stanford algorithm in the "ViroScore-PLUS" Report which provides resistance interpretation based on the patients current and past resistance history. Ronan Boulme, VP of Research and Development added, "Our clinical partners have requested we take into account the historic resistance profile of the patient, even if some mutations were not currently present due to lack of drug pressure. We are proud to announce this functionality when more and more governments and insurance agencies are recognizing the value of genotype testing and reimbursing for its cost."

ABL includes the Stanford Algorithm in version 6.2 of the ViroScore Suite released March 28th and is offering upgrades to existing customers in over 36 countries.

To license the ABL products, to learn about our company or to start a research partnership, please visit www.ablsa.com. ABL is currently seeking a distribution partner for their technologies in the North American region.

Press Contact:
Hank Head
e-mail protected from spam bots
(919) 386-8041

Posted by Industrial-Manufacturing at 02:56 AM | Comments (0)

PanelRx Integrates Clinical Validation with Healthcare Consumer Panels

PanelRx, a new product from the morefocus group, brings together healthcare consumers, physicians and pharmacists to advance marketing and clinical research.

Carlsbad, CA (PRWEB via PR Web Direct) March 30, 2005 — morefocus group inc, a leading on-line research panel manager and publisher, today announced the launch of PanelRx, a new research and marketing tool for the pharmaceutical sector.

Designed to integrate the more than 20,000 physicians in the NCERx clinical investigator panel with the large-scale healthcare consumer database managed by morefocus, PanelRx is able to provide unique insights into doctor/patient interactions. The addition of point-of-service messaging through over 42,000 pharmacists across the US and Canada, allows extreme targeting by condition, geography and therapy.

"The accelerating change in the Rx and OTC marketing environment requires more than just historical prescribing data," said Colin Lucas-Mudd, CEO of morefocus group, "In today’s market, rapid access to, and analysis of, patient and physician attitudes is essential to meet marketing, compliance and persistency goals. Through blending our healthcare subsidiary’s (NCERx) experience in the clinical trial sector, with the on-line panel management and sampling tools applied by morefocus in the consumer sector, we are able meet these goals quickly and cost effectively. In the DTC arena, the potential to optimize media spend and mix is significant."

PanelRx provides a HIPAA compliant route for marketing and clinical researchers to select and survey micro-segmented patient populations directly, with the additional benefit of clinical validation. Dr Richard Scuderi MD PhD., NCERx Medical Director, added, "I am excited by the potential of PanelRx to build patient awareness and influence. The marketing, clinical research, persistency and attitudinal benefits of the product, combined with the ability to generate longitudinal data, have the potential to generate the information needed to meet the sometimes conflicting requirements of manufacturers, managed care organizations, physicians and patients."

Further information on the morefocus group’s clinical and rapid deployment survey and marketing products is available from the NCERx or morefocus websites, or by calling 1.800.549.3904, extension 7005.

About morefocus group inc.
San Diego- and London-based morefocus group inc., builds and maintains on-line permission-based consumer relationships through one of the Internet’s leading healthcare and lifestyle networks. In the healthcare sector, the Group’s networks reach, inform and engage consumers, patients, their caregivers and medical professionals. The network and proprietary behavioral tracking and survey application suite are applied to build large-scale, patient and health-professional panels, shorten the clinical trial process, inform physicians and advance drug marketing to highly targeted audiences.

Media Contact
Trevor Monk
morefocus group inc.
5928 Geiger Ct. Carlsbad, CA 92008
1-800-549-3904 Extension 7005

Posted by Industrial-Manufacturing at 02:56 AM | Comments (0)

Summa Design Announces Continuing Expansion with Opening of Far East Operations Office in Shanghai, China

Summa Design, contract design firm focused on the medical device industry, today announced the opening of their new Far East Operations office in Shanghai, China. The new office extends Summa Design’s reach into the rapidly expanding Chinese market.

Montrose, CO (PRWEB) March 30, 2005 -- Summa Design, contract design firm focused on the medical device industry, today announced the opening of their new Far East Operations office in Shanghai, China. The new office extends Summa Design’s reach into the rapidly expanding Chinese market.

“We are excited to be able to leverage Summa Design’s unique expertise to launch several new initiatives in the largest untapped market in the world,” said Jon Ferris, President & CEO of Summa Design. “Demand for better medical equipment is driving the Chinese market and will increase as the country modernizes to provide healthcare to a population of nearly 1.3 billion people. Our new office will act as a liaison between Chinese medical device companies and their U.S.-based counterparts. We will be facilitating introduction of U.S. devices into Chinese distribution and also helping Chinese medical device companies introduce their products into the U.S. and European markets.”

With one of the fastest growth rates in the world, the Chinese medical equipment market was estimated at $10.6 billion in 2003 and growing at 15% per year. China has more than 300,000 health institutions countrywide including more than 60,000 hospitals.

"Standard of living as well as the elderly population continues to increase steadily in China. Chinese government reforms are aimed at promoting better access to basic health care through increasingly open markets for foreign devices," noted Mr. Ferris. "Our staff in China will be working closely with the State Drug Administration of China on importation and registration of new U.S. devices being introduced.”

The Company
Summa Design is a privately-held company based in Colorado. Their clientele includes medical device companies in need of engineering resources and includes large, established companies as well as small start-ups. The company provides an unparalleled range of services in the industry, including engineering design and development services, marketing, sales, distribution, and FDA and international regulatory consulting. Summa Design is the first contract design firm to offer an industry-leading “VC Partner Program©”, which promotes relationships with venture capital companies and allows Summa Design to introduce start-up clients to funding sources.

Visit their website at www.summa-design.com for more information.

Posted by Industrial-Manufacturing at 02:53 AM | Comments (0)

March 30, 2005

Physician Micro Systems, Inc. Announces Integration of Instant Medical History

Physician Micro Systems, Inc. (PMSI), the creator of Practice Partner electronic health records (EHR), practice management, and computerized physician order entry (CPOE) software, and Primetime Medical Software, Inc., maker of the Instant Medical History patient interview application, today announced that they have integrated Instant Medical History with Practice Partner Patient Records.

(PRWEB) March 30, 2005 -- Physician Micro Systems, Inc. (PMSI), the creator of Practice Partner electronic health records (EHR), practice management, and computerized physician order entry (CPOE) software, and Primetime Medical Software, Inc., maker of the Instant Medical History patient interview application, today announced that they have integrated Instant Medical History with Practice Partner Patient Records.

Using Instant Medical History, a patient can enter his or her complete present illness, review of systems, and medical history information prior to the patient visit – either over the web or using a waiting room kiosk. Instant Medical History summarizes this information and automatically begins a progress note in the patient chart in Practice Partner Patient Records. The physician can then open the patient’s electronic health record, review the patient-entered information, and complete the documentation for the encounter.

By enabling the direct flow of patient-entered information into the electronic health record, the integration of Instant Medical History with Practice Partner will help to reduce clinician data entry, provide more accurate documentation, and improve the focus and efficiency of the patient encounter.

“Instant Medical History offers Practice Partner customers a tool to improve the clinical documentation process and facilitate better physician-patient communication. This partnership furthers our mission to help physicians improve productivity and quality of care,” said Andrew Ury, M.D., founder and president of PMSI.

"Practice Partner customers have long seen PMSI as a leading provider of EHR technology," said Matthew Ferrante, CEO, Primetime Medical Software. "We are delighted to extend our technology to this group of innovative physicians."

Posted by Industrial-Manufacturing at 03:48 AM | Comments (0)

Baxa CEO Greg Baldwin Joins Healthprolink Board of Directors

Greg Baldwin, Chairman and CEO of Baxa Corporation of Englewood, Colorado, has joined the Board of Directors for Healthprolink of Bellevue, Washington. Baxa Corporation, a privately held company, is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in over 35 countries.

Englewood, CO (PRWEB) March 30, 2005 -- Greg Baldwin, Chairman and CEO of Baxa Corporation of Englewood, Colorado, has joined the Board of Directors for Healthprolink of Bellevue, Washington. “Greg brings a wealth of industry experience and insight to the Board, states Terry Gibbons, Chairman and CEO of Healthprolink. “His knowledge and experience will deepen the strong foundation of Healthprolink’s Board of Directors.”

Healthprolink, Inc. is the developer of the software products Quantifi, UnitStock and MedAtlas, designed to support strategic pharmacy management and clinical documentation. Baxa Corporation is a world leader in providing systems to hospital pharmacies for handling, packaging and administering fluid medications. The two companies operated for several years under a co-marketing agreement that promoted synergy in sales and marketing opportunities while Healthprolink gained critical mass among their hospital pharmacy constituency. Baxa Corporation retains a financial interest in Healthprolink, though their sales and marketing efforts are now independent.

Greg Baldwin formerly served as President of and CEO of Baxa Corporation from November, 1997 to April, 2003. Baldwin had been Senior Vice President for Worldwide Sales and Marketing at Baxa since joining the company in 1993.

Prior to joining Baxa, he worked for ten years in sales and marketing management for the telecommunications industry. A graduate of Bowdoin College (Brunswick, ME), Baldwin holds an MBA from Boston University, serves on the Board of the Colorado BioScience Association and is a Trustee of Denver Academy, a grades 3-12 school for children with learning differences.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

About Healthprolink
A leader in clinical software solutions for the healthcare industry, Healthprolink provides HIPAA-compliant applications that document, report, and benchmark clinical activity, and solutions for meeting JCAHO requirements. Healthprolink’s solutions improve patient care, reduce costs and provide financial justification for clinical programs. Serving thousands of healthcare professionals in 416 hospitals across the United States, Healthprolink is based in Bellevue, Washington. Further information is available at http://www.healthprolink.com.

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303-669-3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:46 AM | Comments (0)

Summa Design Announces Continuing Expansion with Opening of Far East Operations Office in Shanghai, China

Summa Design, contract design firm focused on the medical device industry, today announced the opening of their new Far East Operations office in Shanghai, China. The new office extends Summa Design’s reach into the rapidly expanding Chinese market.

Montrose, CO (PRWEB) March 30, 2005 -- Summa Design, contract design firm focused on the medical device industry, today announced the opening of their new Far East Operations office in Shanghai, China. The new office extends Summa Design’s reach into the rapidly expanding Chinese market.

“We are excited to be able to leverage Summa Design’s unique expertise to launch several new initiatives in the largest untapped market in the world,” said Jon Ferris, President & CEO of Summa Design. “Demand for better medical equipment is driving the Chinese market and will increase as the country modernizes to provide healthcare to a population of nearly 1.3 billion people. Our new office will act as a liaison between Chinese medical device companies and their U.S.-based counterparts. We will be facilitating introduction of U.S. devices into Chinese distribution and also helping Chinese medical device companies introduce their products into the U.S. and European markets.”

“Our staff in China will be working closely with the State Drug Administration of China on importation and registration of new U.S. devices being introduced,” noted Mr. Ferris.

With one of the fastest growth rates in the world, the Chinese medical equipment market was estimated at $10.6 billion in 2003 and growing at 15% per year. China has more than 300,000 health institutions countrywide including more than 60,000 hospitals. Both urban standard of living as well as the elderly population continues to increase steadily. Chinese government reforms are aimed at promoting better access to basic health care through progressively more open markets for foreign devices.

The Company
Summa Design is a privately-held company based in Colorado. Their clientele includes medical device companies in need of engineering resources and includes large, established companies as well as small start-ups. The company provides an unparalleled range of services in the industry, including engineering design and development services, marketing, sales, distribution, and FDA and international regulatory consulting. Summa Design is the first contract design firm to offer an industry-leading “VC Partner Program©”, which promotes relationships with venture capital companies and allows Summa Design to introduce start-up clients to funding sources. Visit their website at www.summa-design.com for more information.

Posted by Industrial-Manufacturing at 03:44 AM | Comments (0)

March 29, 2005

Taking Temperature Doesn't Get Any Easier Than This

Technology seems to have solved the age-old problem of temperature measurement with the development of the new Forehead Thermometer that uses advanced infrared technology.
Technology seems to have solved the age-old problem of temperature measurement with the development of the new Forehead Thermometer that uses advanced infrared technology.

Taking temperature doesn't get any easier than this.

Sooner or later every child gets sick and has a fever. When this occurs, it can be very helpful to know exactly what the child’s temperature is. You want to know whether there is only a slight fever or if the fever is possibly at a dangerous level that requires urgent medical attention. Over time, you then also want to know if the fever is going up or down with treatment.

But taking an accurate temperature has long been a problem for parents. Until now.

Digital thermometers that parents use to take the temperature under the arm have always been popular, but their biggest disadvantage is that they take so long to register a reading. It is not always easy to hold a thermometer under a child’s arm for a minute or two when the child is sick, distressed and possibly wriggling around.

Ear thermometers overcome this problem by recording the temperature within a couple of seconds. But they have one major disadvantage. Many parents report huge difficulty using them, especially on infants. Parents often state that if they take the temperature more than once, they get very different results each time. This is usually because it can be difficult to get the probe deep enough into the child’s ear to record an accurate reading. As such, many parents find ear thermometers inaccurate and unreliable.

But technology seems to have solved the age-old problem of temperature measurement with the development of the new Forehead Thermometer that uses advanced infrared technology. This amazing product measures the temperature on the child’s forehead and gives an accurate and reliable temperature reading within 2 seconds.

The Forehead Thermometer has the following major advantages over other thermometers:
- It is much easier to use than all other thermometers.
- It is much gentler on the child than oral, rectal, underarm and in-ear thermometers because it is truly non-invasive.
- It is exceptionally accurate and reliable.
- It is the most hygienic of all thermometers.
- The temperature of the patient is not only displayed on the screen but is also spoken out loud.
- Best of all, it can be reliably used on newborns, infants, children or adults.

And when you consider all of these significant advantages, in conjunction with the fact that it costs a great deal less than ear thermometers, the Forehead Thermometer is clearly an essential item for any family, especially one with small children!
For further information or high resolution pictures call Frances on 0407-140500 or contact e-mail protected from spam bots

Posted by Industrial-Manufacturing at 02:50 AM | Comments (0)

March 28, 2005

Can Pfizer and Wyeth Compete with Dynamic Hemorrhoid Market Place Contender Home Solutions Health, Inc

Home Solutions Health, Inc. (OTC: HSHL:PK)diligently pursuing agreements that would get the product into drug stores and nationwide retail chains.

New York, NY (PRWEB) March 25, 2005 -- Home Solutions Health, Inc. (OTC: HSHL:PK) www.hemorrelief.com a market leader in providing a cost effective relief from the discomfort of Hemorrhoids via its patented and FDA approved HemorRelief™ product is announcing its intent to overhaul all of its core marketing materials to better position the company in the overwhelming demanding marketplace. Home Solutions Health, the licensee of Hemorrelief, explains that 75% of Americans will experience symptoms from hemorrhoids during their lifetime. More importantly 100 million Americans suffer from occasional hemorrhoid pain that can develop at any time. Hemorrhoid sufferers subsequently spend over $2 billion a year on treatment with 3.5 million seeking advice from a doctor.

“We believe it is critical at this juncture in our company’s development to invest resources into our marketing processes, as today’s enlightened consumer is seeking products and services from company’s that present the right image,” said Steven Bingaman, CEO of Home Solutions Health, states, "Hemorrelief is in its 2005 sales penetration phase is securing partner agreements with medical device distributors. We plan to use these distributors to seize market share in retail over-the-counter sales to hemorrhoid sufferers, our most important embedded market segment. We are diligently pursuing agreements that would get the product into drug stores and nationwide retail chains. This type of shelf exposure could quickly position high-value Hemorrelief as a household name similar to Wyeth Pharmaceuticals product Preparation H, Stock Symbol: (WYE) Stock Exchange: (NYSE) or Pfizer product Tucks Stock Symbol: (PFE) Stock Exchange: (NYSE).

Our aggressive distributor marketing strategy has already generated inquiries from European, Middle East and Asian distributors that could quickly place Hemorrelief in the international markets. Accordingly, we have been interviewing and meeting with several top tier advertising agencies and intend to select one of these agencies within the next few weeks.

Hemorrelief is an effective, patented, FDA approved, low-cost treatment for the burning, itching and severe pain associated with hemorrhoids. It reduces swelling for more than 90% of all hemorrhoid sufferers. " Hemorrelief is the cool way to relieve Hemmorhoid Pain" www.hemorrelief.com.

Home Solutions Health, Inc. (OTCPK: HSHL) is a well established medical products company that offers an FDA approved and Patented treatment for Hemorrhoid relief. The company has shipped thousands of units of its flagship product, HemmorRelief using a direct sales model via its ecommerce enabled web site and through distribution partners. The company is developing additional products that will be based on its existing technology that will be announced in the near future. For more information: www.hemorrelief.com, 1.888.436.5665, e-mail protected from spam bots

This release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the company’s current views with respect to future events that involve risks and uncertainties including uncertainties related to successful negotiations with other parties, closing of transactions, capital availability, operational and other risks, uncertainties and factors described from time to time in the company’s publicly available SEC reports. In light of these risks and uncertainties, the forward-looking events described in this release might not occur.

Posted by Industrial-Manufacturing at 04:44 AM | Comments (0)

March 25, 2005

OTOVATION Announces New Amplitude Line of PC Audiometers

Amplitude line of PC-based audiometers for hearing professionals, physicians, schools, and occupational health testing markets.

(PRWEB) March 25, 2005 -- OTOVATION today announced its new Amplitude line of PC-based audiometers. Amplitude addresses the need for efficient and portable audiometric testing on a standard Windows PC.

The first model in the Amplitude line, the A1, is based on a headset that can be connected directly to a USB port on a PC running the Amplitude software. The Amplitude A1 is designed to make audiometric testing quick and easy, portable, and usable on a wide variety of existing PC's as well as the latest of tablet and ultra-portable PC's.

Some of Amplitude A1's features:
* USB connection to a desktop, laptop, tablet or ultra-portable PC
* Connect headset to PC, load Amplitude software, and be ready for testing in about a minute
* Keyboard, mouse, and touch-screen capable interface
* Built-in patient database and easy, flexible operation
* 11 frequencies from 125 to 8k Hz and intensity range from -10 to 110 dB HL
* Manual or automated (Hughson-Westlake) testing
* Optional bone conduction with masking

The new Amplitude A1 will be demonstrated in OTOVATION's booth 505 at the American Academy of Audiology Conference and Expo in Washington, DC from March 31st through April 2nd.

The Amplitude A1 will be available on June 1st through OTOVATION's growing network of partners and distributors.

Posted by Industrial-Manufacturing at 02:34 AM | Comments (0)

March 24, 2005

Baxa Corporation Celebrates 30 Years of Product Safety and Innovation for Hospital Pharmacies

In March 1975, two entrepreneurs with experience in pharmacy sales and product development started Baxa Corporation, a medical device company focused on products that ensured patient safety. Thirty years later, the company’s first product – a dispenser dedicated to safe delivery of oral medications – is still the market leader, alongside a full line of devices and systems designed to streamline fluid drug handling, admixture and packaging activities in hospital and alternate-site pharmacies.

Englewood, CO (PRWEB) March 24, 2005 -- In March 1975, two entrepreneurs with experience in pharmacy sales and product development started Baxa Corporation, a medical device company focused on products that ensured patient safety. Thirty years later, the company’s first product – a dispenser dedicated to safe delivery of oral medications – is still the market leader, alongside a full line of devices and systems designed to streamline fluid drug handling, admixture and packaging activities in hospital and alternate-site pharmacies. Baxa Corporation saw organic growth in the 1970’s and early 1980’s through the development of close relationships with key national opinion leaders and the company’s dedication to understanding the needs of hospital pharmacists, and designing products that specifically addressed those sterile compounding needs.

The company’s second decade was characterized by organic expansion through market innovation, as it launched a series of unique products, such as the Repeater™ Pump – the first designed for accurate pharmacy filling. This was followed by the introduction of the MicroMacro™ Automated Compounders, the first to combine high speed for large-volume transfer, with accuracy for micro-ingredient delivery. By the end of its second decade, Baxa has added a dual rate syringe infuser and the Exacta-Mix™ Universal Pump to its line of products supporting pharmacy efficiency.

“It’s not thirty years of achievement that is so rewarding,” states Brian Baldwin, Founder and Chairman Emeritus, “It is the fun and excitement of the journey. My dream of building a truly great business is a continuous work in progress.” Brian and co-founder Ron Baxa both remain active in the business today, complementing the leadership of Brian’s sons Greg and Jeff Baldwin.

Through its focus on state-of-the-art technology for automating sterile compounding and improving other pharmacy procedures, Baxa Corporation gained a reputation as a leader in application knowledge and product innovation. That reputation led the company’s strategic growth in the 1990’s and allowed them to partner with companies such as Abbott Laboratories (now Hospira), Samson Technologies, Fujisawa and others to enhance the value of their product offering.

“Baxa always demonstrated technical expertise,” notes Jeff Baldwin, President and COO, “but it was our focus on customers that has built the business to what it is today. Targeting an underserved market and finding ways to change their operations to improve efficiencies has helped build a base of true Baxa “fans” in hospital pharmacies.”

Today, Baxa Corporation is nearing $100 million in annual sales, with 300 employees at its Englewood, Colorado headquarters. Reaching this 30-year anniversary milestone reflects the dedication of Baxa associates and the loyalty of the company’s customers worldwide. “Our mission,” says Greg Baldwin, Baxa Chairman and CEO, “has been to build lifelong customer relationships by providing the most innovative devices and systems for handling, packaging and administering liquid medications. Our success over the past 30 years is tangible proof that we are living that mission.”

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

###

Link to CEO Greg Baldwin's Expert Profile at:
http://expert411.com/_wsn/page7.html

Posted by Industrial-Manufacturing at 04:16 AM | Comments (0)

Columbus Children's Hospital Inc. Selects Galvanon to Facilitate At-Risk Screening Program for Adolescents

Self-service technology will enable self-assessments for a broad spectrum of health risks.

Maitland, FL (PRWEB via PR Web Direct) March 23, 2005 — Galvanon, the patient experience company, today announced that Columbus Children's Hospital Inc. has selected Galvanon's MediKiosk™ and eClipboard solutions to support the organization’s clinical research department in fulfilling the requirements of the Trial of Automated Risk Appraisal for Adolescents (TARAA) Project, a self-report health screening of youth at-risk behavior.

Funded by a grant from the National Institute on Drug Abuse, the program screens youth for their use of alcohol and other drugs, symptoms and impairments for co-morbid mental disorders, and other at-risk behaviors. By utilizing Galvanon’s technology, Columbus Children's Hospital will be able to improve its screening services and provide primary care physicians with immediate, reliable and valid results for each participating youth.

"Unfortunately, many barriers exist to routing screening and monitoring in primary care settings, including the expense of traditional paper and pencil screening, complex scoring programs, competing demands on primary care clinicians and office staff, and the ability to track youth over time," said Kelly J. Kelleher, M.D., M.P.H., director of the office of clinical sciences at Columbus Children’s Hospital. "Galvanon's technology provides us with exceptional tools to complete this important screening process and manage the resulting research."

Galvanon will automate the user identification and questionnaire completion process through its Customer Value Management (CVM) Enterprise Server, a common platform that facilitates the seamless exchange of information between MediKiosk, eClipboard and the facility's existing IT systems.

"The flexibility of Galvanon’s technology in building and conducting questionnaires makes it a perfect fit with the objectives of the TARAA program and will allow researchers to present questions in an intuitive way that prompts users to answer additional questions based on previous responses," said Clynt Taylor, CEO of Galvanon. "Whether conducting a survey or checking in patients, the simple and compound logic embedded in our self-service technology provides all of the tools necessary to gather vital patient information efficiently and effectively."

About Galvanon, Inc.
Galvanon helps healthcare organizations enhance the patient experience at home, in the hospital and in the physician’s office through innovative solutions such as kiosks, Web self-service applications and technology that streamlines everyday patient interactions and improves patient flow through the healthcare process. For more information, visit www.galvanon.com/healthcare.

Press contact:
Cathi Hilpert
e-mail protected from spam bots
407-667-0669

Sales Contact:
Gary Anthony
e-mail protected from spam bots
817-832-1060

Posted by Industrial-Manufacturing at 04:15 AM | Comments (0)

Arkansas Rottweiler Jasmine Breaks World Record with 24 pups - Canadian Pet Medicine Web Site Helps Huge Family with Donation of Medicines, Supplies

Rescue center dog's record litter of 24 pups gets support from www.universalpetmeds.com with free medicines. Shop provides high-quality, low-cost medications via internet at up to 50 percent savings.

(PRWEB) March 23, 2005 -- There’s a male dog who could be popping his buttons in South Central Arkansas these days. After all, he’s the father of a record 24 pups born to a single litter at the Critter Holler Animal Rescue in South Central Arkansas.

But, unfortunately, he’s an absentee father and won’t be there to take care of his brood, and his wife, Jasmine, who live at the Rescue. Not to worry, however, thanks to www.universalpetmeds.com, a leading internet supplier of high-quality, low-cost medicine supplies for animals, which has ‘adopted’ Jasmine and the pups through supplying free medicines and food for Jasmine and her puppies.

“Our online pet pharmacy, www.universalpetmeds.com, provides pet supplies to pet owners all over the world. Our main focus is small animal health which for the most part entails the health of dogs and cats," explains Paul Turner, marketing director for www.universalpetmeds.com.

“Charlie Campbell, who does such wonderful work with his rescue service, contacted us,” “I guess he realized that this was something extraordinary, and he needed some moral support.

”We are totally committed to preserving the health of our clients’ pets—and the welfare of animals generally-- by offering a complete line of important medications, at savings of up to 50 percent of prices in the U.S., so it was only natural that we would respond to assist the Center, Jasmine—and, of course, the 24 puppies,” Turner says.

“Another goal was to show our support for the important work that Charlie and others do in animal rescue,” Turner concluded.

Critter Holler Animal Rescue, Inc.’s web site is http://www.critterholler.com . Pet owners interested in savings for important pet medications may visit www.universalpetmeds.com.

Posted by Industrial-Manufacturing at 04:15 AM | Comments (0)

DDL Package Testing Services Launches Packreview - ISO 11607 Clause 6 Certification Unveiled at HealthPack 2005

DDL Testing Services launches PackReview, a certification, granted by DDL, to demonstrate package compliance with ISO 11607 clause 6

San Antonio, TX (PRWEB) March 23, 2005 - http://www.TestedAndProven.com/PackReview-news.html - DDL Testing Services, a MN-based package, product and material testing laboratory, will debut its PackReview (SM) ISO 11607 clause 6 certification service at the HealthPack conference in San Antonio, TX, March 23 – 24, 2005.

PackReview is the DDL approved ISO 11607 clause 6 certification granted to packages that have successfully endured rigorous package testing in order to demonstrate compliance with ISO 11607 (clause 6).

“With the help of Pack Review, DDL provided invaluable assistance in formulating a test plan for our device packaging to meet FDA and ISO requirements,” said Laura Bauer of Raymedica. “They knocked months off our timeline and were there to help every step of the way. They will be the first place we call when another packaging project comes up.”

The ISO 11607 clause 6 packaging for terminally sterilized medical devices standard is defined by the FDA and the EU as the paradigm validation protocol for medical device packaging.

DDL Package Testing Engineers are proud to offer PackReview as an addition to their suite of growing PackServices.

“As a leading medical device package testing laboratory, we are committed to providing high quality testing services to our clients,” said Patrick Nolan, DDL Testing Services COO. “Our intention is for PackReview to become recognized industry-wide as a respected certification that verifies a package’s compliance with ISO 11607 clause 6.”

"The PackReview certification program should be helpful to medical companies needing a full service packaging validation process,” said Wayne Schmidt, Sr. Manufacturing Engineer, Arizant Healthcare Inc."

DDL package testing experts will be showcasing PackReview at HealthPack 2005, March 23 - 24, in San Antonio, TX.

Request the Getting Started with PackReview ISO 11607 Clause 6 Certification Startup Kit, which includes a protocol outline at: http://www.TestedAndProven.com/PackReview-news.html.

About DDL
DDL offers expert package testing services that provide superior testing and excellent documentation for package testing, material testing, product testing and HazMat testing. DDL package testing clients find peace of mind with the DDL reliable PackReview (SM) ISO 11607 clause 6 certification. DDL maintains full service testing labs in Minnesota and California.

Contact DDL at: http://www.TestedAndProven.com/PackReview-news.html or call Scott Levy at 952-941-9226 ext.115

Posted by Industrial-Manufacturing at 04:13 AM | Comments (0)

March 22, 2005

Alliances and Outsourcing Having Major Impact on Pharma Industry

Evidence of the growing emphasis on alliances and external collaborations as a route to success in the pharma industry is highlighted by the fact that partnerships within the biopharmaceutical sector are currently being formed at the rate of $5 billion per year, according to Arrowhead Publishers' new report Strategies for Innovation in Pharmaceutical R&D: Enhancing R&D Through Biotech Alliances and CRO Outsourcing (http://www.arrowheadpublishers.com/StrategiesforInnovationinPharmaceuticalRandD.html)

(PRWEB) March 22, 2005 -- The modern pharmaceutical company faces numerous challenges in its efforts to improve productivity and to strengthen the product portfolio. In an attempt to counteract the pressures of operating in a global pharmaceutical market, companies have sought to establish relationships with external partners such as biotechnology companies and Clinical Research Organizations (CROs) as a means to remaining competitive and profitable.

Alliances and external collaborations have provided companies with the opportunity to gain access to new technological breakthroughs and novel expertise regardless of national or geographical boundaries. Evidence of the growing emphasis on alliances and external collaborations as a route to success is highlighted by the fact that partnerships within the biopharmaceutical sector are currently being formed at the rate of $5 billion per year.

This new report from Arrowhead Publishers is designed to provide information, insight and in-depth analysis of alliance and licensing activity within the pharmaceutical industry in order to identify the challenges faced by members of the pharmaceutical community; current trends in partnering activity; an understanding of the dynamics of the buyer-supplier relationship and best practices for managing external collaborations. The report is aimed at providing an appraisal of the partnering process, and insights into the current environment of pharmaceutical discovery and development.

Strategies for Innovation in Pharmaceutical R&D includes the following features:
• A thorough market analysis of the global pharmaceutical industry, including the challenges faced by pharmaceutical manufacturers and the technological developments currently affecting innovation
• Guidelines for partnership management, with profiles of market leaders in the areas of pharmaceuticals, biotechnology and clinical research
• An informative and vital source of reference that provides practitioners with easy to access case studies, tabular data, key competitor profiles and a glossary of key pharmaceutical terms and definitions, with details of alliance and licensing deals within the biopharmaceutical sector
• A review of key developments taking place in the environment of pharmaceutical R&D and an evaluation of possible strategies for facilitating the drug discovery and development process
• Analysis of the significance of biotechnology to the pharmaceutical industry, including key trends in pharmaceutical alliance and licensing agreements
• An assessment of the importance of outsourcing to the drug development process, and an overview of the market for contract research, including key trends in pharmaceutical licensing agreements.

Contact:
Sales Department
952-474-5203
www.arrowheadpublishers.com

Posted by Industrial at 03:02 AM | Comments (0)

Hospital Grade Cream Provides a Beauty Friendly Option to Cure Skin Cancer from Sunbeds

The topical cream, Curaderm-BEC, can eliminate skin cancer caused by sunbed use. This is welcoming news for sunbed lovers alarmed by last week's World Health Organization public warning on risks associated with sun bed use and UV in general.

(PRWEB) March 22, 2005 -- Manufacturer of Curaderm-BEC, has confirmed today the product's capacity to eliminate skin cancer from UV lights attached to sunbeds. This is welcoming news for sun bed lovers, and the multibillion dollar tanning industry who are concerned by last week's World Health Organization (WHO) public health crisis warning on UV and sunbed dangers.

UV exposure in sunbeds, like sunlight, often causes tiny red dots, known as sun spots. Spots often then evolve into larger, non melanoma BCC's or SCC's.

When diagnosed, patients are usually treated by surgical excision of the cancer. Healthy glowing tanners are often subject to skin cancer treatments that cause loss of body tissue and scarring. If the cancer appears on the face, plastic surgery may be necessary to restore a normal appearance.

Dermatologists at Royal London Hospital and nine other United Kingdom skin cancer treatment centers have now confirmed that Curaderm-BEC cream can eliminate all traces of non melanoma skin cancer. Treatment is available for damage from both indoor and outdoor UV exposure.

Curaderm-BEC consists of a patented biochemical (BEC) which is extracted from plants and a specialized cream formulation. Keratolytic and other agents in the cream soften and peel of the first layer of skin allowing the anti-cancer bio-chemical BEC to reach deep into the affected skin tissue. The cream is applied topically twice a day to BCC or SCC non melanoma skin cancer lesions or sun spots.

Clinical research and over twenty years of medical research and information on the side effects of both sun bed and outdoor tanning is available online at www.curaderm.net. This includes the product's coverage in prestigious medical publications such as Drugs of Today and Cancer letters.

Previously, the product was only available in Australia (skin cancer capital of the world) where over 50,000 people have used the product. Due to the rapid growth in new skin cancer cases, Curaderm-BEC is now available online for customers anywhere.

People who maintain a tan should regularly check for sunspots or skin cancers and, upon recognizing one, take immediate action. Immediate treatment virtually eliminates any melanoma cancer risk. Most Caucasians will have at least one skin cancer by age 60

Posted by Industrial at 03:01 AM | Comments (0)

March 21, 2005

PepperSlim Herbal Infusion Hits Big With Health Conscious Consumers and Beverage Drinkers

A small company known for big results with its hot pepper based natural herbal remedies, has created a new liquid weight loss health supplement designed to be mixed with nearly any beverage. This unusual concentrated extract of pepper, mushroom and cinnamon is said to increase metabolism and reduce appetite while promoting overall good health.

Albany, NY (PRWEB) March 21, 2005 -- PepperSlim Herbal Infusion, a small company known for big results with its (hot pepper based) natural herbal remedies, has come up with a new liquid weight loss health supplement designed to be mixed with nearly any beverage, including spring water, ginger ale and green tea.

This unusual concentrated Pepper/Mushroom/Cinnamon extract is said to rev up the metabolism and reduce appetite while promoting overall good health.

PepperSlim Herbal weight loss infusion is a highly concentrated tincture derived from five varieties of gourmet mushrooms and three varieties of classic hot peppers.

The key to the sales success of this unique product appears to be the addition of organic cinnamon bark oil for an uncomparable taste that mixes particularly well with water, iced tea and ginger ale. Barely 5 drops of this strange formula mixed into a 16-ounce bottle of water provides results that are quite astounding.

The manufacturer also claims PepperSlim adds an energy boosting, thirst quenching sensation that really "kicks it up a notch" for any beverage.

“Not only does PepperSlim quench your thirst like nothing else, but it also reduces your appetite while helping to increase metabolic activity," says Wayne Perry, president of SiCap Industries, the company that produces PepperSlim. "The more you use, the more burn you feel.

"We also believe that PepperSlim helps boost the immune system, which also aids in the increased energy most people feel when they use it. The best thing is the concentrated compounds found in cinnamon and capsaicin could potentially reduce bad cholestorol and help regulate blood sugar levels. It’s a phenomenal product that deserves to be tested by the research world,” Perry said.

SiCap Industries stands for: “Science Of Capsaicin,” a well deserved moniker for the creators of the world’s first hot pepper nasal spray known as “Sinus Buster.” Released in late 2003, Sinus Buster has fast become the most talked about natural remedy, relieving a host of chronic sinus, allergy and headache conditions. Sinus Buster has more than 50,000 regular customers who first discovered this seemingly “miraculous cure” thanks to Oprah Winfrey, Howard Stern, the Wall Street Journal and the World Wide Web.

Perry, also the inventor of Sinus Buster, first discovered the medicinal power of hot peppers after appearing on the Oprah Winfrey Show during the mid 1990s. Perry was a nationally recognized self defense instructor who suffered from chronic headaches. At the time, Perry was promoting his self defense video titled: "Beating The Crime Clock," in which he was sprayed with real pepper spray for the cameras.

After teaching Oprah Winfrey to use self defense pepper spray on her show, Perry quickly became known as a "Pepper Spray Expert" being sprayed by nearly every self defense spray on the market in an effort to test their effectiveness and publicize his video.

After his first Oprah appearance, Perry was deluged with requests from television stations around the country to perform live pepper spray demonstrations. Then one day while performing a live demonstration for a local television news crew, Perry was stricken with one of his debilitating headaches. He continued with the demonstration only to find out that the pepper instantly stopped his headache. Perry had never experienced one of his headaches during a live spray demonstration before, but he instantly knew he had stumbled onto something very significant.

By 2002, Perry had perfected his secret formula using several hot pepper extracts. Through trial and error experimentation, Perry realized that in order to be effective the pepper had to be delivered through the nose, and so he created "Sinus Buster" the world's first commercial hot pepper nasal spray.

Perry's formula quickly became a local hit and also proved to be much more than a mere headache equalizer. It turned out that this hot pepper formula also relieved chronic sinus and allergy conditions far beyond the scope of modern medicine. Today, Sinus Buster is known as a true medical breakthrough, and is backed by hundreds of physicians and researchers throughout the world.

In 2004, SiCap Industries and Sinus Buster got a huge boost from a small plug on the Howard Stern Radio Show. Sales boomed and calls flooded in. Next came an article in the Wall Street Journal touting Sinus Buster as the next big thing in natural medicine. Since that fateful day nearly eight months ago, Sinus Buster has become an international phenomenon with projected 2005 sales figures in the millions.

"Thanks to Howard Stern and the Journal," Perry says. "Once the ball started rolling it just continued to grow. Every month, Sinus Buster sales grow by 10% with a solid 28% growth every fiscal quarter and no extra investment as far as marketing. Most of our success is due to word of mouth and media exposure. Of course we wouldn't get that exposure if it wasn't for the fact that buster really works, and now we're building on that success with the launch of PepperSlim," says Perry.

With the official launch of SiCap’s new PepperSlim infusion, the company expects to become the world’s authority on natural metabolic health. SiCap officials say PepperSlim is perhaps the world’s first "true natural health tonic" that reduces overactive appetites while increasing metabolic activity.

Moreover, this unique formula is also potentially beneficial to the immune system through its’ high content of Polysaccharides and other compounds derived from the combination of mushrooms used in the base extract. Most importantly, SiCap officials point out that the combination of Cinnamon and Capsaicin could aide in reducing high cholesterol and high blood sugar.

There are many studies supporting SiCap's claims about mushrooms, capsaicin and cinnamon. In fact, two recent studies concerning cinnamon showed it to be beneficial for controlling Type 2 Diabetes, and for reducing high cholesterol levels.

One study by the U.S. Department Of Agriculture (USDA) showed that as little as one gram a day of cinnamon (one quarter of a teaspoon twice daily) can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL or “bad” cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent.

Furthermore, Capsaicin (the active chemical in hot peppers), has been proven to increase blood flow and help regulate blood pressure while also reducing appetite. Other studies also show medicinal mushrooms to be potential cancer fighters with super immune boosting power.

“We took everything we’ve learned from working with the sinus buster nasal formula to create a pepper supplement that could be taken orally. The result has been astounding. PepperSlim is so concentrated that only as few drops in a bottle of water or iced tea is equivalent to eating nearly an eighth of a pound of hot peppers and mushrooms. The secret to our Pepperslim base is our exclusive peppershroom extract. We start with creating an extract made from fresh Shiitake, Maitake, Reishi and Oyster Mushrooms mixed with Habanero, Jalapeno and Cayenne peppers infused in a natural very expensive 160 proof vodka. After the brewing process has worked for at least 30 days, we add Oleoresin Capsicum, organic Green Tea extract and organic Cinnamon Bark oil to the mix. It takes nearly two months from start to finish to produce one batch of the pepperslim base extract,” explains Perry.

The result is a concentrated herbal infusion that delivers seemingly instant results. This thirst quenching infusion adds a semi-hot (peppery -- cinnamon) flavor and aroma to nearly any beverage. Within the first minute of drinking PepperSlim, the company claims your appetite will be effectively reduced. Furthermore, SiCap officials say PepperSlim also increases metabolic activity and overall energy levels in a noticable way when taken as directed.

“Beyond the basics of weight control and healthy blood flow, we believe PepperSlim could also prove to be a natural fortifier for the immune system," he says. "Our hope is that just like with Sinus Buster, researchers will begin to study the potential of peppers and mushrooms ingested in concentrated forms through tinctures.

"There are a few revolutionary drugs available right now that include compounds found in mushrooms. It’s also widely believed by researchers that the low rates of intestinal and colon cancer in South America are directly related to a diet that’s heavy in Capsaicin, the key ingredient in hot peppers. We know it helps to boost the metabolism and it’s excellent for preventing blood clots that can lead to strokes and heart attacks,” says Perry.

When SiCap first introduced PepperSlim this past January, the product took off quickly thanks to a constant stream of visitors at SiCap’s main website (www.sinusbuster.com). Now barely three months after its’ initial launch, PepperSlim is selling in the thousands, and repeat customers are already booming. SiCap has testimonials from customers around the world, and many are using PepperSlim in more than just simple water.

“A lot of our customers are giving us specific feedback concerning the use of PepperSlim in beverages. The biggest winners are Canada Dry Ginger Ale, Seven Up, Aquafina water, Diet Coke and Green Tea. Especially Snapple Green tea with lime and Honest Tea Green Dragon. PepperSlim really does taste great. It gives a mild cinnamon taste to any beverage, but it also has that pepper heat sensation. The more drops you put in a beverage, the more heat sensation you get, but the cinnamon levels out quickly without overpowering the taste so it's the perfect addition to all kinds of drinks -- even martinis," jokes Perry.

Although SiCap officially recommends adding 3-7 drops of PepperSlim to a 16 ounce bottle of water, it seems customers are continuing to find new combinations on an almost daily basis.

Perry says the best thing about PepperSlim is that it won't overpower the taste of any liquid. It simply adds to the overall bouquet. So the amount is up to the user based on his or her tastes. SiCap also plans on seeking out a beverage manufacturer interested in adding PepperSlim to one of their bottled drinks sometime before summer.

"We're thinking a venture deal with a quality beverage company could be interesting and profitable. We may even have our own brand private labeled, but I'd personally rather hook up with a manufacturer who already has brand recognition and launch the product that way," says Perry.

To find out more about PepperSlim Weight Loss Infusion or Sinus Buster, visit the main SiCap website at (www.sinusbuster.com). Samples and information packets are available for qualified media and medical personnel upon official request.

Posted by Industrial at 02:57 AM | Comments (0)

Fighting Off The Killer Flu: Innovative Advances in Immune Health May Save You!

Dr. Nancy Cox, Chief Influenza Scientist at the US Centers for Disease Control stated, “The ‘very frightening’ outbreak of virulent Bird Flu in Asia could lead to the most devastating human pandemic in history.” Klaus Stohr, Global Influenza Co-Coordinator of the World Health Organization (WHO), warns “the planet is overdue for a killer flu outbreak.”

(PRWEB) March 21, 2005 -- Dr. Nancy Cox, Chief Influenza Scientist at the US Centers for Disease Control stated, “The ‘very frightening’ outbreak of virulent Bird Flu in Asia could lead to the most devastating human pandemic in history.” Klaus Stohr, Global Influenza Co-Coordinator of the World Health Organization (WHO), warns “the planet is overdue for a killer flu outbreak.”

With alarming frequency, we are being warned about the threat posed by the “Bird Flu.” According to the WHO, this lethal H5N1 avian influenza has decimated poultry populations in East and South-East Asia. The poultry infection may create opportunities for a new influenza virus strain to spread easily among humans. The world is unprepared for such an event.

Vaccination, our primary defense, helps protect against the next flu season but not against unexpected strains. In fact, manufacturers have been wrong about the “up and coming” strains for the past three years.

Stohr said a dozen countries, led by Australia, Canada, France, the US and Sweden, bought stockpiles of Roche’s antiviral drug, Tamiflu®, Tamiflu® acts as a prophylactic and is also indicated for treatment of influenza infection in adults who have been symptomatic for no more than two days but is untested against any new flu pandemic strains. Of course, as with any engineered drug, side effects can be problematic. And the effects of Tamiflu® on children under 18 and pregnant women have not yet been determined.

So how can we as individuals protect ourselves? Strengthening the immune system is imperative. The truth is our first recourse should be the medicinal properties nature offers, and millions already take supplements. But what is not widely understood is that the beneficial nutrients are either destroyed by the acids in the stomach or the indigestible caplet/capsule containing the nutrients passes through the body intact.

Fortunately, there is a solution. Cape Cod Biolab Corporation (CAPE COD) developed and patented a revolutionary advancement called BIO-SHIELD®. Originally, BIO-SHIELD® was developed to overcome the degradation of the natural cranberry bio-activates as they pass through the stomach. In clinical tests, this supplement, CRAN-MAX®, reduced the occurrence and duration of Urinary Tract Infections (UTIs) in patients by 50% to 90%. Released in 1997, CRAN-MAX® is now recommended by many doctors to maintain urinary tract health.

BIO-SHIELD is a very exciting innovation with far-reaching implications. CAPE COD introduced ANTI-MAX®, formulated by Bio-Chemist, MD, Tom Hesslelink. ANTI-MAX® utilizes the BIO-SHIELD® technology to successfully deliver a combination of all-natural, selected anti-oxidants which boost the immune system. Natural ingredients include ELDER-MAX®, an elderberry fruit compound with anti-viral activities, GINGER-MAX®, a ginger oil compound with anti-inflammatory and anti-emetic activities, GREEN-MAX®, a green tea extract with anti-microbial, anti-carcinogenic and anti-inflammatory activities, and BLACK-MAX®, Nigella sativa oil with anti-histamine and anti-carcinogen activities. Thus the name “ANTI-MAX®.” These natural herbs, oils and fruit strengthen the immune system which greatly enhances your body’s ability to fight off infection and illness, including influenza.

Selected SARS patients in the Toronto, Canada outbreak, voluntarily took ANTI-MAX® and recovered significantly faster than those using traditional medicines alone. This is a very exciting development, and formal clinical trials are pending.

Dr. Rose practices ophthalmology in Los Angeles and is president of the Rose Eye Medical Group. He is on the Life Extension Foundation (www.lef.org) Medical Advisory Board and the staffs of Pacific Alliance Medical Center in Los Angeles and other area hospitals.

by: Marc Rose, MD

Posted by Industrial at 02:55 AM | Comments (0)

March 18, 2005

Baxa Introduces Four New Microfuse Infusion System Administration Sets

Baxa Corporation announces the addition of four specialty administration sets to the MicroFuse® Syringe Infusion System line. These new sets incorporate a T-site for the convenient administration of coronary vasodilators during myocardial perfusion imaging. Their design resulted from customer feedback on safety and ease of administration for this specialty cardiac application.

Englewood, CO (PRWEB) March 18, 2005 -- Baxa Corporation announces the addition of four specialty administration sets to the MicroFuse® Syringe Infusion System line. These new sets incorporate a T-site for the convenient administration of coronary vasodilators during myocardial perfusion imaging. Their design resulted from customer feedback on safety and ease of administration for this specialty cardiac application.

The new MicroFuse Administration Sets feature an integrated, T-site injection port close to the set outlet. This easy-access port facilitates the addition of a secondary medication during cardiac monitoring procedures, minimizing the opportunity for medication error or the introduction of touch contamination. Prior to their release, the available selection of administration sets was limited. The sets offer needleless ports and are available in several convenient lengths to accommodate different clinical practices.

“Baxa has offered a specialty infuser for vasodilation procedures for many years,” explains Mark Thrasher, Market Manager for IV administration products. “The new sets were developed from discussions with cardiac clinics and their technicians. Providers had very specific input on set length, connector types, and specific configurations. They made it easy to respond with products that addressed specific needs.”

The MicroFuse Rapid Rate Infuser is the most popular device for simple, cost-effective administration of adenosine. The new sets complement Baxa Corporation’s existing product line for pharmacologic stress imaging. MicroFuse Administration Sets have a low prime volume to minimize drug waste. Their integrated Y and T connectors make them safer and more efficient than competitive sets used for this application.

Baxa developed the MicroFuse Rapid Rate Infuser specifically for rapid infusion of adenosine during pharmacologic imaging procedures. To accommodate this specialty application, MicroFuse Rapid Rate Infusers deliver a full syringe dose over approximately six or eight minutes, depending on physician requirements.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com

Contacts:
Marian Robinson
Vice President, Marketing
Baxa Corporation:
800.567.2292 ext. 2157
303.617.2157

Maggie Chamberlin Holben
APR
Absolutely Public Relations
303.984.9801
303.669.3558

Posted by Industrial at 03:44 AM | Comments (0)

March 17, 2005

DDL Testing Services Recruits MTS Veteran - New Materials Product Manager Grows DDL Product/Material Testing Dept.

Minneapolis, MN (PRWEB) March 17, 2005 -- http://www.testedandproven.com – DDL Inc., a MN-based package, product & material testing laboratory, has recruited MTS veteran Alan Gale as its new materials product testing manager, in an effort to expand its product and material testing department.

DDL recognizes that the material and product testing market is rapidly growing, particularly in the medical device industry. Since 2004, DDL has seen its medical device product testing sales rise from 5% to 15% of its total business.

“Recruiting Alan Gale is a strategic move on our part,” said John Hart, DDL President, “we are eager to take advantage of his tenured experience and product test expertise in order to further expand our product and material testing department.”

Throughout his 27-year career at MTS Systems Corporation, where he held various positions from Project Engineer, Technical Support Specialist to Inventory Manager and Product Manager, Gale was constantly recognized by management for “excellent performance, exceeding position requirements and work planning goals”.

“DDL has state-of-the-art product testing machinery in place in its laboratory, including sophisticated tensile testing systems and vibration testing machines,” said Gale. “I am delighted to lead a product and material testing department which obviously has so much potential.”

In addition to DDL materials and product testing services, Gale will be offering “PackAdvice”, complimentary pre-and-post product, materials and package testing consultation, designed to help DDL customers achieve and exceed compliance with industry standards.

About DDL Testing Services & DDL West:
DDL offers expert package testing, product testing and material testing services including Shock testing, vibration testing, tensile testing, leak testing and validation. DDL package testing clients find value through its zero-cost package testing consulting service, PackAdvice. DDL Testing Services maintains full service testing labs in Minnesota and California.

Contact DDL at www.TestedandProven.com or call Scott Levy at 952-941-9226 ext.115

Posted by Industrial at 05:12 AM | Comments (0)

FDA Approved Temodar

The U.S Food and Drug Administration's approval of Temodar as a treatment for people newly diagnosed with glioblastoma recognizes the importance of hope. These reports signify movement in the treatment of one of the most aggressive brain tumors.

(PRWEB) March 17, 2005 -- The U.S Food and Drug Administration’s approval of Temodar as a treatment for people newly diagnosed with glioblastoma recognizes the importance of hope. A study published by Roger Stupp, MD, for the European Organization for Research and Treatment of Cancer (EORTC) in last week’s New England Journal of Medicine found that adding Temodar to radiation therapy increased survival rates to 26.5% at two years (from 10.4 % with radiation alone). In an equally compelling report also published in the same journal, studies at the University Hospital of Lausanne indicate the interaction between this drug and a biologic marker called MGMT may provide important information for researchers. These reports signify movement in the treatment of one of the most aggressive brain tumors.

Glioblastoma multiforme is the most common of the primary malignant brain tumors, and is also one of the most difficult tumors to treat effectively. Each year, approximately 20% of all reported brain tumors are glioblastoma. Generally found in people forty through sixty years old, glioblastoma occurs slightly more often in males than females. This tumor tends to be found in the cerebral hemispheres of the brain that control memory, thinking abilities, personality, and movement.

The American Brain Tumor Association offers information about glioblastoma multiforme and Temodar; about other types of brain tumors and their treatments; about standard therapies as well as research treatments; and about support options for brain tumor families seeking help in living with the diagnosis of a brain tumor. Call us at 800-886-2282, or visit our web site at www.abta.org
Physicians available for interviews.

This week’s headlines share our hope… the hope that new knowledge brings to the quality of lives of brain tumor patients around the globe.

Contact:
American Brain Tumor Association
2720 River Rd.
Des Plaines, Il 60618
847-827-9910
www.abta.org

Posted by Industrial at 05:11 AM | Comments (0)

March 15, 2005

US FDA Approves Marketing of Biomove 3000 for Stroke Rehabilitation. The Highly Affordable Home Therapy System Enters U.S Market

US FDA approves marketing of the highly affordable and easy to use Home Stroke Therapy device Biomove 3000 http://www.biomove.com manufactured by the Israeli company Curatronic Ltd.

(PRWEB) March 15, 2005 -- Hashmonaim, Israel --- Curatronic Ltd. announced today that it has obtained U.S. Food and Drug Administration (FDA) marketing approval for the Biomove 3000 Stroke Rehabilitation system.

The Biomove 3000 system was specifically developed for home therapy following a stroke. The highly affordable battery-powered device detects extremely small electrical EMG signals that persist in paralyzed muscles after a stroke and uses these tiny signals to initiate an electrical stimulation impulse to the muscles, resulting in actual muscle movement by the patient.

FDA 510(k) approval allows Biomove 3000 to be marketed in the United States, where over 700,000 individuals experience a stroke each year. Millions of people suffer from the debilitating effects of stroke. Fifty percent have some one-sided paralysis and seek effective treatment for their severe, long-term disabilities.

Ben Philipson, President of Curatronic Ltd. said, "We are delighted to have received FDA approval for the Biomove 3000 system, which enables us to reach the many stroke victims in the US market with our economical, easy-to-use system.

Further information about the Biomove 3000 system can be found at Curatronic’s Biomove web site: http://www.biomove.com

Curatronic Ltd. was founded in 2000 as a privately held R&D company dedicated to developing affordable, easy to use state-of-the-art stroke rehabilitation and therapy devices for use by patients at home and by professional therapists.

Curatronic Ltd.
P.O.Box 1532
Hashmonaim
73127 Israel
Tel: 011-972-8976-1441
Fax: 011-972-8976-2020

Posted by Industrial at 11:57 PM | Comments (0)

March 14, 2005

Mediabids, the Only Online Print Ad Space Marketplace, Saves Client, Green River Prescription Assistance, 82 Percent On Newspaper Advertising Costs

Organization saves 82 percent on newspaper advertising costs with help from online agency Mediabids

Winsted, CT (PRWEB) March 14, 2005 -– Sara Mattingly founder of the organization Green River Prescription Assistance (www.grpap.org) came to Mediabids for help reaching people who need the services they provide; assistance to patients who are U.S. residents, low income and have no prescription insurance.

Mediabids.com’s media planner Kris Cianciolo was able to deliver newspaper advertising space and many extras at a savings of over 82 percent in a high circulation weekly newspaper. Through Mediabids, Mattingly paid $100 for over $560 of advertising space; four 3.79”w x 7” h, B/W insertions and production included.

"I can’t say how pleased I am to have found Mediabids. I started this organization three years ago with no funding and knew nothing about advertising. Now I’m promoting our services nationwide and the process of advertising has become an even more daunting task. Kris and the staff at Mediabids have made the process of planning, purchasing and designing advertising simple and cost effective. Moving forward I plan on using Mediabids for all grpap.org advertising purchases. " – Sarah Mattingly, Founder, www.grpap.org

Register your business or find more information on this easy way to purchase newspaper advertising and magazine advertising on www.MediaBids.com or call direct at 866-236-2259. Registration is free, simple, and confidential.

The average savings offered to businesses needing to purchase newspaper advertising and magazine advertising is 61% on advertising rates. Advertisers are never obligated to make a purchase if they are not satisfied with the offers received from publications. There is no fee to use Mediabids services, advertisers pay only for the price of the newspaper advertising and magazine advertising space they purchase.

About MediaBids.com
Mediabids has developed a better way for advertisers and publications to buy and sell newspaper advertising and magazine advertising. Mediabids, the newspaper and magazine advertising auctioneer, offers a unique opportunity for advertisers and publications to tap into new markets, increase revenues and save on costs traditionally associated with print advertising. A Connecticut-based newspaper company founded Mediabids in 1999 as a tool to streamline and enhance the relationship between advertisers and print media outlets. www.mediabids.com, toll free 866-236-2259

Posted by Industrial at 11:55 PM | Comments (0)

New Open MRI Matches Innovative Technology with Patient Comfort and Ease

New technology spares patients the claustrophobia of conventional MRI. This system now available in the Baton Rouge area at The Pain Treatment Center and First Choice Surgery Center.

Baton Rouge, LA (PRWEB) March 14, 2005 -- For people who fear small, enclosed spaces, the MRI diagnostic test can be their worst nightmare. The test can be long, and lying in an enclosed chamber is tasking on any patient.

Thanks to the new MRI technology available at The Pain Treatment Center and First Choice Surgery Center, the MRI process just got easier. Installed in December 2004, the high performance premium “open” Hitachi Airis II MRI system offers patients a less threatening environment, allowing them to rest easier during testing. For some patients, it means the difference between sedation and no sedation.

The demand for “open” MRI systems and services over the conventional “closed” MRI systems by patients and physicians has been increasing dramatically during the past few years. Claustrophobia, size and weight of the patient or issues related to patient comfort are the contributing factors.

“Patients and their referring physicians will be happy to know the open MRI is not only more comfortable for patients, it also delivers more powerful, faster results,” said Arnold Feldman, M.D., medical director of the Pain Treatment Centers of Baton Rouge and Natchez and the First Choice Surgery Center. “This particular system offers award-winning gantry design, combined with high-speed gradients and state-of-the-art computer and magnetic technology. In short, patients are receiving the best technology available in a more comfortable environment and convenient location.”

MRI or magnetic resonance imaging provides an unparalleled view inside the human body without the use of X-rays. The level of detail shown through MRI is extraordinary compared with any other imaging modality. MRI is the method of choice for the diagnosis of many types of injuries and conditions because of the incredible ability to tailor the exam to the particular medical diagnosis. Although it has been available for the last two decades, MRI has seen tremendous improvements over the past few years with continued advances in technology. “Better diagnosis of the problem translates to improved treatment faster,” said Feldman. “It’s a win-win for patients and their families. For some patients, the open MRI means no sedation needed and quicker results without the anxiety factor.”

To learn more about the advanced open MRI technology at The Pain Treatment Centers and First Choice Surgery Center, or to set up an appointment call 225.201.0950

The Pain Treatment Centers: Arnold Feldman, M.D., a Harvard trained anesthesiologist specializing in pain management, is dedicated to bringing new technologies and procedures to his state-of-the-art facilities in Baton Rouge, La. and Natchez, Miss. The Pain treatment Centers offer relief from chronic and acute pain relating to back and neck injury, migraines, sports injuries, arthritis, cancer and many other disorders. For more information or to schedule an appointment, call 225-201-0950 or visit www.paintreatmentcenterinc.com

Posted by Industrial at 11:54 PM | Comments (0)

March 13, 2005

Signal Expands Power Isolation Transformer Offering to Include Units Optimized for Medical Equipment

Signal Transformer today announced the expansion of their M4L Series of International Power Isolation Transformers to include the 450 VA rated M4L-1-4, M4L-2-4, and M4L-3-4

Inwood, NY (PRWEB) March 13, 2005 -- Signal Transformer, a subsidiary of Bel Fuse Inc. (NASDAQ: BELFA & BELFB), today announced the expansion of their M4L Series of International Power Isolation Transformers to include the 450 VA rated M4L-1-4, M4L-2-4, and M4L-3-4. These transformers are for use in providing reinforced isolation between Mains supply and sensitive electronic equipment. The new parts join the Company's comprehensive offering of standard and custom power transformers for worldwide applications, and are in full compliance with the leakage and insulation requirements as stipulated by the IEC 61558-1-2 and UL safety standard 60601-1. Signal’s chassis mount devices feature a non-concentric winding platform to provide reinforced isolation and superior dielectric performance. The high efficiency, laminated transformers furthermore boast a vertical-mount configuration to minimize their footprint, and a modular “touch safe” terminal assembly to prevent shock hazards.

Signal’s newest transformers are ideally employed in a broad range of such medical and dental instruments as EEG monitors, electro-surgical equipment, hospital beds, portable lab cabinets, sterilizing equipment, medical grade linear power supplies, data processing isolation, and ultrasonic devices.

The entire M4L transformer series is dielectric strength tested to 4.0 kV, offers an extremely low, less than 30 microamp, leakage current, and incorporates a UL Recognized class F (155 degrees C) insulation system. Rated @ 50/60 Hz, the series provides operational voltages of 115 V, 230 V and 100-115/200- 230 V. These highly efficient transformers utilize low-loss magnetic steel and UL 94 V0 flame rated polymers. Measuring 4.5” (114.3 mm) L x 4.33” (109.9 mm) W x 4.5” (114.3 mm) H, and weighing 11 lbs. (5.0 Kg), Signal’s power transformers for medical applications feature quick-connect/screw type terminals.

In 100 unit quantities, pricing on the M4L series ranges from $59.50 to $62.45 each depending on operational voltage. Delivery is from stock to 6 weeks.

About Bel
Bel (www.belfuse.com) and its subsidiaries are primarily engaged in the design, manufacture and sale of products used in networking, telecommunications, high speed data transmission, automotive and consumer electronics. Products include magnetics (discrete components, power transformers and MagJack(R) connectors with integrated magnetics), modules (dc-dc converters, integrated analog front end modules, custom designs), circuit protection (miniature, micro and surface mount fuses) and interconnect devices (passive jacks, plugs and cable assemblies). The Company operates facilities around the world.

Information contained in this news release (including information regarding Signal transformers optimized for medical applications) may constitute forward-looking statements, which involve risks and uncertainties. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercializing or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC report.

Signal Transformer Inc.
500 Bayview Ave.
Inwood, NY 11096
866/239-5777; Fax: 516/239-7208
www.signaltransformer.com

Editorial Contact:
Donna Marganella
858/676-9650; Ext. 108

Posted by Industrial at 11:21 PM | Comments (0)

March 12, 2005

Oxford Performance Materials, Inc. Selects Gsell Engineering Plastics for Machining of OXPEKK® Implantable Polymer

European Customers of Implantable OXPEKK® Get More Supply Options

Enfield, CT (PRWEB) March 12, 2005 -- Oxford Performance Materials, Inc. (OPM) and Gsell Engineering Plastics AG (Gsell) have come to an agreement which enables Gsell to sell machined components produced from OXPEKK® implantable polymer. OPM's OXPEKK®-IG products have undergone ISO-10993 biocompatibility testing and are supported by a FDA Masterfile. This agreement allows manufacturers of implantable devices to purchase raw materials from OPM or finished machined devices directly from Gsell.

“It is our position that limiting device companies to the purchase of raw materials can result in burdensome supply chain costs”, said Scott DeFelice, President of OPM. “We have previously established a processing partner in the US for the implantable market and now we are pleased to extend to European customers a comparable arrangement. The European market is very dynamic and can best be serviced by firms experienced with the local business environments. This new relationship with Gsell will allow our customers the flexibility to do business in a manner most consistent with their individual circumstances.”

“Gsell is a premier European supplier of implantable machined polymer products. They have the experience and relationships to service our mutual customers in a highly efficient and professional manner. We are very pleased that our European market development strategy is now accelerating”, said Mr. DeFelice. Due to the nature of implantable materials and technical requirements, OPM will limit processing partner agreements to only those firms that meet the exacting technical standards established by OPM and its ultimate customers.

“Gsell Engineering Plastics specializes in machining of polymers for medical implants,” said René Gsell, President of Gsell. “We are continually looking for materials and technologies that our customers will find desirable. Our relationship with OPM will enable a more advantageous business process requested by our customers with a technologically advanced product.”

Founded in 1984, Gsell is a Swiss company specializing in machining of high performance plastics. The firm produces a broad range of implantable and other critical products to its customers exacting specifications, serving the European marketplace. Please visit Gsell Engineering Plastics at www.gsell.ch

Founded in March 2000, OPM has rapidly become an industry leader in the ultra-high performance thermoplastic polymers market. The firm's versatile OXPEKK® polymers are currently being used in the space and defense, medical, semiconductor, and industrial markets worldwide. For additional information, please visit www.oxfordpm.com

Posted by Industrial at 11:19 PM | Comments (0)

Pain Treatment Center Patients Relieved from a Lifetime of Pain with the FDA Approved 'Pain Pump'

'Pain Pump' targets site of pain and allows more relief to patients. Arnold Feldman, M.D. of the Pain Treatment Centers of Baton Rouge and Natchez is now performing this procedure on a limited release basis.

Baton Rouge, LA (PRWEB) March 12, 2005 -- Arnold Feldman, M.D., of The Pain Treatment Center of Baton Rouge has been using the Medtronic SynchroMed II implantable pump since April 2004, as part of Medtronic’s limited market release, during the recent FDA study. The pump proved itself to be a life altering option for patients with chronic pain, many with a history of unsuccessful surgeries and procedures. Outcomes have been excellent, and for patient Heather Englehart, the result is relief from two decades of chronic pain.

In 1982, Englehart was 104 lbs of strength and resolve. Her job on a horse farm required her to lift hay bails that weighed almost as much as she did. She developed a shooting pain in her back, but ignored it as long as she could. Soon she found herself in complete, constant pain. After two failed back surgeries, she was certain she would never ride a horse again.

Englehart was one of the 40 million people in the United States who are affected with musculoskeletal pain. To make matters worse, a large percentage of chronic pain sufferers have undergone multiple failed surgeries and will experience a lifetime of pain, relieved only by pain medications.

“The oral medications took the edge off, but they didn’t make me comfortable,” said Englehart. “Now I can stand for a long time without running home to lie down. My friends have even noticed that I’m a happier person. For the first time since my failed surgery, I am hopeful I may ride again.”

Oral pain medications have long been the primary treatment option for patients with chronic pain, intractable pain or severe spasticity. These drugs cannot target the exact origin of pain and carry several adverse side effects. With Medtronic’s SynchroMed II implantable pump, specially formulated medications are delivered directly to the intrathecal space, the fluid-filled area surrounding the spinal cord. This site-specific delivery targets the medication’s site of action in the spinal cord, thereby minimizing the dose requirements and side effects compared to oral administration of the same drugs.

“Patients require programs specific to their needs,” said Feldman, Chief Physician at The Pain Treatment Center. “There are times when pain cannot be resolved through traditional treatments and medications. In these cases, the ‘Pain Pump’ maximizes the patient’s quality of life.”

The Pain Treatment Centers: Arnold Feldman, M.D., a Harvard trained anesthesiologist specializing in pain management, is dedicated to bringing new technologies and procedures to his state-of-the-art facilities in Baton Rouge, La. and Natchez, Miss. The Pain treatment Centers offer relief from chronic and acute pain relating to back and neck injury, migraines, sports injuries, arthritis, cancer and many other disorders.

For more information or to schedule an appointment, call 225-201-0950 or visit www.paintreatmentcenterinc.com

Posted by Industrial at 11:17 PM | Comments (0)

March 11, 2005

Apex Foot Health Industries to Change Name, Rocket into the Future with New Product Divisions

Foot Health Leader Rebrands for the 21st Century

Teaneck, NJ (PRWEB) March 11, 2005 -- After more than half a century as a worldwide leader in the therapeutic footwear and foot care industries, Apex Foot Health Industries looks to the future with a major rebranding effort that will include changing the company's name and brand structure. Effective May 1, 2005, Apex will be known as Aetrex Worldwide, Inc.

The name change partially stems from the overwhelming success of the company's Aetrex Performance Footwear line, introduced early last year to various markets. “The success of the Aetrex line became symbolic of a whole new direction for our company,” says Larry Schwartz, CEO. “In the 20th century we built a brand that represented the highest quality products for foot comfort, therapy and protection. We will continue to offer these fine products, but will also expand our casual and athletic footwear lines, introducing innovative designs that provide the utmost in comfort and performance while satisfying demands for the latest 21st century styles.”

Aetrex Worldwide will be offering three unique catalogs of products – Aetrex Performance Products, Apex Healthcare Products and Aetrex Technology & Education. The Technology & Education catalog will highlight the popular high-tech software and Internet products that Apex has introduced to the footwear industry, including iStep digital foot analysis systems and the web site Foot.com, which hosts more than 200,000 visitors per month.

The company has promised that all current Apex products will remain in the lines, including Ambulators, Ariyas, Lyncos, Anti-Shox, and more. In addition, this summer Aetrex will introduce several unique new athletic styles including new running shoes, hiking footwear and athletic walkers.

“The name Aetrex was originally chosen because it means One Journey,” Schwartz continues. “Your life really is your own unique journey, filled with activities and challenges that help define who you are. The Aetrex mission is to bring to market products and technologies that enable you to continue these activities throughout your life, persevere through challenges and live the life you love.”

Apex Foot Health Industries will officially become Aetrex Worldwide, Inc. on May 1, 2005. The company is headquartered in Teaneck, NJ and currently employs 145 people, including 24 board certified pedorthists. For more information please contact Donille Perrone, Director of Marketing at 800-526-2739, ext. 325

Posted by Industrial at 11:15 PM | Comments (0)

Six Straight Years of Double-Digit Medical Rate Increases Has Had a Significant Impact on Both Employers and Employees

Hay Group reviews how companies are turning to innovative approaches to contain ever-rising medical costs. Six Straight Years of Double-Digit Medical Rate Increases Has Had a Significant Impact on Both Employers and Employees

Philadelphia, PA (PRWEB) March 11, 2005 -- Company medical insurance premiums for 2005 rose approximately 10%, representing the sixth year of double-digit rate increases. These increases are sharply higher than the US Consumer Price Index that was 3.3% for 2004, and an average annual 2.7% for the last six years.

Stated in terms of payroll, employer costs for health benefits have risen steadily from 7.28% in 2000 to over 9% for 2005, according to the Hay Benefits Report, a cross-industry survey of more than 1000 US companies.

“This is a very difficult time for companies to cope with double-digit medical premium rate increases,” said Michael Carter, Vice President in Hay Group’s Benefit Practice. “In the current business environment, most companies simply cannot afford to pass these costs along to their customers.”

As a result, to maintain current levels of profitability, companies are likely faced with shifting medical costs to employees, exploring new strategies to contain rising medical costs, as well as cutting costs in other areas.

“There is no one ‘silver bullet’ solution to contain medical costs, so companies must use multiple strategies,” says Hay Group’s Carter. He adds that “the longer companies wait to address the issue, the more painful it could be for them or their employees.”

Traditional Cost Containment Measures Still Used
Companies continue to negotiate with insurers and administrators and bid coverage when necessary to get the best rates. Organizations also continue to consolidate medical plan offerings and funding.

Another traditional strategy is to shift more costs to employees. Many companies pay a fixed percentage of the premium, so when average premiums rise 10%, then employees’ costs rise 10%. In addition, companies have been increasing employee deductibles, co-payments, and the limit at which employees’ out-of-pocket expenses are capped.

One of the most striking changes in the last three years has been the increase in employee co-payment for doctor visits, with most plans having a co-pay of $15 or more in 2005 versus just under half of the plans in 2002.

Companies Look to Innovative Approaches
“Frustrated with the inability of traditional approaches to sufficiently contain medical increases, companies have turned to innovative approaches,” said Carter. These include changes to prescription drug and retiree medical plans as well as introduction of wellness and disease management programs, health savings accounts, and employee consumerism.

Prescription Drugs
Because prescription drugs have accounted for the largest portion of medical cost increases, employers have been raising plan co-payments, as they have for other medical services. In addition, they have adopted one or more of the following strategies:

- Increasing the difference between generic, brand, and non-formulary co-payments;
- Revising from employee dollar co-pays to percentage coinsurance (which automatically indexes);
- Requiring mandatory generic when available; and/or
- Requiring mail order for maintenance drugs.

Retiree Medical
For companies providing over 65 retiree medical coverage, the new 2006 Medicare prescription drug benefit will offer some relief from the high cash outlay and accounting expense of this coverage. Companies are currently determining whether they can lower their cost more in 2006 and beyond by taking the government’s payment for continuing the coverage or by reducing their plan design to supplement the new Medicare prescription drug benefit.

Wellness and Disease Management
Historically, companies have provided “wellness” programs that include preventive exams, health programs such as smoking cessation, and health club memberships -- all aimed at improving employees’ general health. Companies also have offered “case management” programs aimed at controlling costs of major illnesses.

Disease Management focuses on improving the health -- and thus controlling the costs -- of common manageable diseases. These include diabetes, asthma, congestive heart failure, coronary artery disease, and hypertension. These voluntary programs, now in place in most companies, are designed to prevent the state of the disease from advancing, and where possible, to result in improvement.

New Health Savings Accounts
Health Reimbursement Accounts (HRA) and Health Savings Accounts (HSA) along with “high deductible” plans are also emerging as cost containment strategies. These new types of plans involve a company-funded HRA or employee- or company-funded HSA that employees can use for IRS-approved health expenses -- including some items not typically covered in medical plans. Unused amounts can be carried over to the following year, in theory encouraging employees to become better healthcare consumers. Supplementing the HRA/HSA is a “high-deductible” plan, with typical annual deductibles ranging from $1000 to $3000 per individual.

Less than one-fifth of companies report offering as an option an HRA, high-deductible plan, or both. Typical employee participation in these options is reported at less than 10%. In 2005, less than 10% of companies have adopted HSAs with high-deductible plans.

Employee Consumerism
In addition to the strategies described above, “employee consumerism” is a new strategy used by some of Hay Group’s clients. This involves communicating to employees how medical cost increases affect them (e.g., higher employee costs, lower pay increases, lower staffing levels) and what they can do about it (e.g., improve health, use Disease Management, use 24-hour medical assistance services, ask questions of your provider, check insurer charges).

“Just as you would want to do your research to make an informed decision before buying a big-screen TV,” reflected Carter, “people should become better consumers of healthcare. Employers should educate and inform their employees about considering their options before blindly following their doctor’s recommendations. They should ask, for example, ‘Can I use a generic drug in place of the brand name?’ Employee consumerism enables clients to enlist their employees in the battle to control healthcare costs.”

HMOs Lose Their Edge over PPOs
Premium costs for HMO and Point-of-Service (POS) plans that require Primary Care Referrals for specialists and tests are rising as fast as the cost of PPO plans that do not have that requirement. Historically HMO and POS plan premium increases have been less than PPO increases.

“HMOs’ traditional ability to contain costs better than PPOs has disappeared in the last two years,” says Mr. Carter. “This is probably due in part to HMO and POS plans easing up on restricting referrals for care in response to litigation and consumer and government pressures.

“HMOs would rather do the easing up (on restricting referrals) themselves rather than have the government regulate it,” Carter continued. Another reason may be increased pressures on HMOs to raise provider reimbursement levels to come closer to PPO reimbursements.

According to the Hay Benefits Report, HMO and POS plans have been declining in prevalence as the primary plan offered by employers. In 2000, almost half of companies had HMO or POS plans as their primary plan. This has dropped to just a third of companies for 2005. “This shift reflects growing employer and employee discontent with the required referrals for specialists and tests in HMO and POS plans” noted Carter.

Exploring Causes for Continuing Rising Medical Premiums’ Costs
Medical costs have been rising for a number of reasons. One reason is that reimbursement rates to hospitals and physicians are on the rise. In the second half of the 1990s, HMO and PPO plans held down reimbursement rates to the point where healthcare providers took action to gain increases. For example, hospitals have been merging into larger systems, sometimes with physician networks, giving them more bargaining power in their negotiations with insurers.

Another cause of rising medical costs is continuously improving medical technology, which allows very sick people to live longer, and thus incur significant medical expenses. Prescription drug costs increasing at a rate exceeding 15% are another cause of rising medical expenses. Rapidly rising malpractice premiums have also contributed to the problem. Other factors include the aging of the workforce and the fact that Americans have become increasingly less healthy, especially in the areas of weight, diabetes, and heart disease.

What’s In Store for the Future?
Looking ahead to plan changes for 2006, more cost shifting is likely. However, Hay Group’s Carter cautioned that “there is a limit to the amount that companies can shift costs to employees, particularly lower-paid employees.” With the average annual employee premium contribution for family coverage reaching $2600 in 2005 along with increasing co-payments, companies will need to rely on strategies other than cost shifting. “Disease Management and wellness programs, which lower costs by improving employees’ health, currently are the best long-term strategies for controlling costs,” said Carter.

About Hay Group
Hay Group (www.haygroup.com) is a global organizational and human resources consulting firm that helps its clients -- Boards, CEOs, Executives, and HR Managers -- on virtually all aspects of their people-related business issues. Founded in 1943, Hay Group has over 2,200 employees working from 77 offices in 76 cities and 43 countries.

Our areas of expertise include:
- Design and analysis of organizations and jobs;
- Talent management through assessment, selection, and
development of executives, managers, and teams;
- Compensation, benefits, and performance management;
- Executive remuneration and corporate governance; and
- Employee and customer attitude research.

Hay Group works with nearly three-quarters of FORTUNE’s top-50 Most Admired Companies, as well as many mid-sized and non-profit corporations, public institutions, and governments.

For Mor